![Kathryn Haviland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Haviland
Presidente presso
FULCRUM THERAPEUTICS, INC.
Patrimonio netto: 171 943 $ in data 31/08/2026
Profilo
Kathryn Haviland è nel consiglio di Fulcrum Therapeutics, Inc. e direttore operativo di Blueprint Medicines Corp., membro della Harvard Business School Health Industry Alumni Association e membro del Biopharma Executive Council. La sig.ra Haviland ha occupato in precedenza la posizione di vicepresidente delle malattie rare presso Idera Pharmaceuticals, Inc., responsabile dello sviluppo commerciale presso Sarepta Therapeutics, Inc. e direttore esecutivo dello sviluppo commerciale presso PTC Therapeutics, Inc. Si è laureata alla Wesleyan University e ha conseguito un MBA alla Harvard Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 09/06/2026 | 7.437 ( 0,01% ) | 171 943 $ | 31/08/2026 | |
| 30/06/2026 | 0 ( -.--% ) | - $ | 31/08/2026 | |
AVALYN PHARMA INC -.--% | 30/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Posizioni attive di Kathryn Haviland
| Società | Posizione | Inizio |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Presidente | 10/01/2022 |
| BICARA THERAPEUTICS INC. | Direttore/Membro del Consiglio | 21/09/2023 |
| AVALYN PHARMA INC. | Direttore/Membro del Consiglio | 01/03/2026 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Corporate Officer/Principal | - |
GC Therapeutics, Inc.
 GC Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops stem cells | Presidente | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Kathryn Haviland
| Società | Posizione | Fine |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Amministratore Delegato | 01/01/2026 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 01/12/2015 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Kathryn Haviland
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
87
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Genzyme, Inc. | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Commercial Services |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
GC Therapeutics, Inc.
GC Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops stem cells | Commercial Services |
